Does Levalbuterol (Xopenex®) Live Up to the Hype?
2008-09-02
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Does Levalbuterol (Xopenex®) Live Up to the Hype?
Authors
Published Date
2008-09-02
Publisher
Type
Other
Abstract
Asthma, in general, is a respiratory disorder that affects millions of Americans each year.
Reasonably priced, effective treatments have been developed by several pharmacological
companies designed to treat this condition by various mechanisms. Levalbuterol has recently
been developed and marketed as a direct beta2 agonist with improved efficacy in symptom relief
as well as an improved side effect profile. A direct superiority study comparing side effect
profiles of both racemic albuterol and levalbuterol concluded that no significant improvement
was noticed with respect to side effect profiles between the two medications.
Keywords
Description
The information provided in this handout does not necessarily reflect the views of the University of Minnesota Medical School physicians and faculty. These materials are provided for informational purposes only and are in no way intended to take the place of the advice and recommendations of your personal health care provider. You use the information provided in these handouts at your own risk.
Related to
Replaces
License
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Voge, Dylan. (2008). Does Levalbuterol (Xopenex®) Live Up to the Hype?. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/42846.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.